Literature DB >> 28775485

HIGH DOSE PULSE DEXAMETHASONE THERAPY IN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Velu Nair1, Vivek Chhabra2.   

Abstract

We studied the response to pulse high dose dexamethasone (DXM) in 12 consecutive patients of symptomatic chronic idiopathic thrombocytopenic purpura (ITP) who had not responded to the standard forms of therapy. All patients had been exhibited to two or more cycles of prednisolone. Besides this 5 patients had also been given danazol and 4 patients had undergone splenectomy. Six cycles of dexamethasone (40 mg per day for 4 sequential days every 4 weeks) were successfully given in all 12 patients. At the end of the sixth cycle there were 7 (58%) complete responders (CR) [platelet count (PLT)100 × 109 /L], 1 partial responder (PR) [PLT-50-100 × 109/L] and 4 non responders (NR) [PLT < 50 × 107L]. Follow up at 1 year showed 4 (33.3%) patients each in CR, PR and NR group. Side effects noted were increased appetite in 8 (66.6%) patients, hyperalertness in 6 (50%) patients, abdominal discomfort in 5 (41.6%) patients and nausea with vomiting in 2 (16.6%) patients. We were not able to identify any chemical or laboratory prognostic parameter which would allow prediction of a successful outcome of this treatment.

Entities:  

Keywords:  Dexamethasone; Idiopathic thrombocytopenic purpura

Year:  2017        PMID: 28775485      PMCID: PMC5531573          DOI: 10.1016/S0377-1237(17)30552-X

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

1.  High-dose dexamethasone therapy in chronic idiopathic thrombocytopenic purpura.

Authors:  V R Arruda; J M Annichino-Bizzacchi
Journal:  Ann Hematol       Date:  1996-10       Impact factor: 3.673

2.  Corticosteroid responsive immune thrombocytopenia in Hodgkin's disease.

Authors:  M Sonnenblick; R Kramer; C Hershko
Journal:  Oncology       Date:  1986       Impact factor: 2.935

3.  Sites of platelet destruction in idiopathic thrombocytopenic purpura.

Authors:  R H Aster; W R Keene
Journal:  Br J Haematol       Date:  1969 Jan-Feb       Impact factor: 6.998

4.  Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies.

Authors:  N R Shulman; V J Marder; R S Weinrach
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

5.  Hematologic aspects of systemic lupus erythematosus. Current concepts.

Authors:  D R Budman; A D Steinberg
Journal:  Ann Intern Med       Date:  1977-02       Impact factor: 25.391

6.  Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin.

Authors:  B Godeau; S Lesage; M Divine; V Wirquin; J P Farcet; P Bierling
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

Review 7.  Management of idiopathic thrombocytopenic purpura in adults.

Authors:  B A McVerry
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

8.  Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.

Authors:  W J HARRINGTON; V MINNICH; J W HOLLINGSWORTH; C V MOORE
Journal:  J Lab Clin Med       Date:  1951-07

9.  Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases.

Authors:  M T Caulier; C Rose; M T Roussel; C Huart; F Bauters; P Fenaux
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

10.  Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia.

Authors:  M Warner; P Wasi; S Couban; C Hayward; T Warkentin; J G Kelton
Journal:  Am J Hematol       Date:  1997-04       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.